recombinant humanized anti-CD25 monoclonal antibody
2024-K387-01
Phase 2 small_molecule active
Quick answer
recombinant humanized anti-CD25 monoclonal antibody for Transfusion Dependent Thalassemia is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Transfusion Dependent Thalassemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active